Screening PD patients treated with LCIG or high doses of levodopa for MTHFR mutations may select a subpopulation of patients with the highest risk of hyperhomocysteinemia-related complications, enabling monitoring this subpopulation and choosing optimal pharmacological therapy. This evidence concerns the gene MTHFR and Parkinson disease.